IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04854590

Enrollment

248

Registered

2021-04-22

Start date

2021-04-22

Completion date

2023-07-25

Last updated

2024-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Small Cell

Brief summary

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

Detailed description

To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

-Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.

Exclusion criteria

-Patients who have no treatment history with the product (i.e.,durvalumab)

Design outcomes

Primary

Measure	Time frame
Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)	16weeks

Countries

Japan

Outcome results